Cravath’s London Office Moves to 100 Cheapside
February 03, 2017
Cravath represented the borrower, Mylan N.V., in connection with the arrangement of a $2 billion senior revolving credit facility, made available by Bank of America, N.A., and a $2 billion senior term loan facility, made available by Goldman Sachs Bank USA. The revolving credit facility will be used to finance working capital needs and for general corporate purposes. The term loan facility will be used to repay existing indebtedness, to finance working capital needs and for general corporate purposes. Mylan N.V. is a leading global pharmaceutical company. The transactions closed on November 22, 2016.
The Cravath team included partner George E. Zobitz and associate Noah X. DeBlasi on banking matters; partner J. Leonard Teti II and associates Kiran Sheffrin and Joyce Y. Kim on tax matters; partner Jonathan J. Katz and associate Matthew J. Bobby on executive compensation and benefits matters; and partner Matthew Morreale on environmental matters. Dean M. Nickles also worked on banking matters.
Deals & Cases
April 29, 2024
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.